Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'
Definium Therapeutics says positive Phase 3 trial results for DT120, shows significant and rapid symptom improvement in anxiety participants.
Definium's anxiety medicine worked really well in testing, which is exciting news for the company. When a medicine shows strong test results, people often watch to see if doctors will approve it and patients will use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.